Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07266441 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
- 20
- Study locations
NCT07266441: Recruiting Phase 2 study of Multiple Myeloma, sponsored by Janssen Research & Development.
NCT07266441 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 157 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07266441, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Conditions Studied
Interventions
- DRUG JNJ-79635322
Study Locations (20)
Other
- Ha'Emek Medical Center - Afula
- Samson Assuta Ashdod University Hospital - Ashdod
- Hillel Yaffe Medical Center - Hadera
- Hadassah Medical Center - Jerusalem
- Rabin Medical Center - Petah Tikva
California
- City of Hope - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
- Cancer and Blood Specialty Clinic - Los Alamitos
Georgia
- Emory University - Atlanta
- Northside Hospital Cancer Institute - Atlanta
Iowa
- University of Iowa - Iowa City
- Mission Cancer Blood - Waukee
Texas
- MD Anderson Cancer Center - Houston
- Oncology Consultants Texas - Houston
Florida
- Cancer Specialists of North Florida - Jacksonville
Illinois
- Cancer Care Specialists of Central Illinois - O'Fallon
New Jersey
- Rutgers Cancer Institute - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2026-02-08 |
| Est. Completion | 2028-12-12 |
| Phase | Phase 2 |
What NCT07266441 shows while recruiting
NCT07266441 is an interventional study that assigns participants to a tested intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which JNJ-79635322 is the first listed.
NCT07266441 names 20 study sites across 11 states, led by Other, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT07266441 about?
NCT07266441 is a clinical study titled "A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refra...
What is the current status of trial NCT07266441?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2026-02-08. Estimated completion is 2028-12-12.
What conditions does trial NCT07266441 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT07266441?
The interventions under investigation include: JNJ-79635322 (DRUG).
Who is sponsoring clinical trial NCT07266441?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07266441 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07266441's enrollment target sits among peer trials
157 129th of 438 higher than 310 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
-
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05052541 · 157 participants · Phase 3
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
- NCT05076942 · 157 participants · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- NCT06396598 · 157 participants · NA
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
- NCT06655246 · 157 participants · Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI